Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E8.77 EPS (ttm)30.21 Insider Own0.10% Shs Outstand156.90M Perf Week-5.36%
Market Cap42.24B Forward P/E10.01 EPS next Y26.48 Insider Trans0.00% Shs Float156.79M Perf Month-1.87%
Income5.08B PEG- EPS next Q5.22 Inst Own88.10% Short Float1.81% Perf Quarter-7.40%
Sales14.26B P/S2.96 EPS this Y44.80% Inst Trans0.04% Short Ratio2.43 Perf Half Y-12.61%
Book/sh68.57 P/B3.86 EPS next Y-21.76% ROA19.60% Target Price305.04 Perf Year-7.24%
Cash/sh22.46 P/C11.80 EPS next 5Y-4.13% ROE42.40% 52W Range257.60 - 374.99 Perf YTD-10.69%
Dividend- P/FCF6.63 EPS past 5Y20.50% ROI30.50% 52W High-29.33% Beta0.56
Dividend %- Quick Ratio1.80 Sales past 5Y8.20% Gross Margin87.60% 52W Low2.87% ATR7.10
Employees7400 Current Ratio2.10 Sales Q/Q-6.20% Oper. Margin46.70% RSI (14)36.20 Volatility3.05% 2.42%
OptionableYes Debt/Eq0.69 EPS Q/Q-46.80% Profit Margin35.60% Rel Volume0.87 Prev Close266.80
ShortableYes LT Debt/Eq0.69 EarningsOct 21 BMO Payout0.00% Avg Volume1.17M Price265.00
Recom2.80 SMA20-5.58% SMA50-5.01% SMA200-9.61% Volume1,014,399 Change-0.67%
Jul-27-20Upgrade Morgan Stanley Underweight → Overweight $263 → $357
Jun-22-20Reiterated RBC Capital Mkts Sector Perform $303 → $273
Jun-22-20Downgrade Barclays Overweight → Equal Weight $370 → $280
Jun-09-20Downgrade Bernstein Outperform → Mkt Perform $360 → $297
Apr-23-20Downgrade Raymond James Mkt Perform → Underperform
Apr-23-20Downgrade Citigroup Neutral → Sell $365 → $240
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $389
Jan-27-20Upgrade Canaccord Genuity Hold → Buy $360
Dec-13-19Upgrade Credit Suisse Underperform → Neutral $260 → $300
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Nov-12-19Initiated SunTrust Buy $337
Nov-01-19Downgrade Standpoint Research Buy → Hold
Oct-30-19Upgrade Bernstein Mkt Perform → Outperform
Oct-23-19Upgrade SVB Leerink Mkt Perform → Outperform $256 → $350
Oct-23-19Upgrade Guggenheim Neutral → Buy $256 → $365
Oct-23-19Reiterated H.C. Wainwright Buy $300 → $335
Oct-23-19Reiterated BofA/Merrill Underperform $200 → $235
Oct-17-19Resumed BofA/Merrill Underperform $200
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Oct-23-20 03:04PM  
Oct-22-20 12:22PM  
11:22AM  
09:44AM  
Oct-21-20 04:16PM  
02:00PM  
01:41PM  
01:34PM  
12:05PM  
10:00AM  
09:51AM  
07:55AM  
07:21AM  
07:10AM  
02:40AM  
Oct-20-20 05:09PM  
11:39AM  
10:08AM  
10:01AM  
Oct-19-20 04:30PM  
07:09AM  
Oct-18-20 11:10AM  
Oct-16-20 03:24PM  
Oct-15-20 07:02AM  
Oct-12-20 06:47AM  
Oct-07-20 10:04AM  
09:35AM  
Oct-06-20 10:00AM  
07:00AM  
Oct-02-20 02:07PM  
06:12AM  
Sep-28-20 12:37PM  
09:55AM  
Sep-23-20 09:30AM  
Sep-20-20 06:53AM  
Sep-16-20 07:00AM  
06:59AM  
Sep-15-20 01:11PM  
07:07AM  
06:18AM  
Sep-14-20 08:00AM  
07:30AM  
06:25AM  
Sep-11-20 08:01AM  
Sep-08-20 04:15PM  
07:30AM  
Sep-03-20 10:15AM  
09:22AM  
Sep-02-20 03:49PM  
Aug-31-20 02:01PM  
Aug-30-20 06:12AM  
Aug-28-20 10:53AM  
Aug-27-20 05:12PM  
05:00PM  
Aug-26-20 05:01AM  
Aug-25-20 07:00AM  
Aug-21-20 10:16AM  
Aug-19-20 12:00PM  
Aug-12-20 12:23PM  
Aug-10-20 11:48AM  
Aug-09-20 08:37AM  
Aug-08-20 10:40AM  
Aug-07-20 05:37PM  
04:41PM  
04:34PM  
04:14PM  
02:23PM  
01:58PM  
01:24PM  
01:24PM  
01:00PM  
09:57AM  
09:56AM  
08:55AM  
08:38AM  
07:41AM  
07:30AM  
Aug-06-20 04:19PM  
09:21AM  
09:13AM  
08:02AM  
Aug-05-20 07:59AM  
Jul-28-20 11:11AM  
Jul-27-20 01:48PM  
12:39PM  
10:20AM  
10:09AM  
07:49AM  
04:09AM  
01:54AM  
Jul-25-20 10:01AM  
Jul-24-20 06:43PM  
04:06PM  
Jul-23-20 02:35PM  
01:08PM  
12:07PM  
Jul-22-20 04:30PM  
04:24PM  
02:20PM  
01:01PM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gregory GingerEVP, Human ResourcesJul 31Option Exercise0.0021204,786Aug 04 04:12 PM
SHERWIN STEPHEN ADirectorMar 11Option Exercise58.4612,278717,77216,517Mar 12 06:56 PM
SHERWIN STEPHEN ADirectorMar 11Sale295.222,434718,57414,353Mar 12 06:56 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.004,847033,775Feb 19 06:20 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 15Option Exercise0.001,213015,019Feb 19 06:17 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.0044102,672Feb 19 06:13 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 15Option Exercise0.001,553037,261Feb 19 06:09 PM
Kramer RobinVP, Chief Accounting OfficerFeb 12Option Exercise0.001320282Feb 14 06:37 PM
Karp DanielEVP, Corporate DevelopmentFeb 12Option Exercise0.0096001,224Feb 14 06:36 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.001,68004,375Feb 14 06:34 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.003,54705,021Feb 14 06:32 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,15402,337Feb 14 06:30 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerFeb 12Option Exercise0.001,91903,732Feb 14 06:27 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.005,967036,389Feb 14 06:25 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0011,994031,483Feb 14 06:19 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.005,216014,509Feb 14 06:16 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,30202,219Jan 06 04:14 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00840175Dec 05 04:24 PM
Posner Brian SDirectorDec 02Sale292.351,055308,4296,995Dec 03 05:58 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0054302,855Dec 03 05:59 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.